Future prospective randomized clinical trials may be warranted to compare the efficacy and safety of the two asparaginase preparations and to optimize the dose and the frequency and route of administration of PEG-asparaginase in adults with newly diagnosed ALL. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.